Gene markers located for hereditary prostate cancer

The panel, gleaned from a study of more than 4,000 Swedes, found that these markers are common and could account for nearly half of the prostate cancer cases in this study. Results are published online in the Jan. 16 edition of the New England Journal of Medicine.

The international research team plans to sample DNA from U.S. populations of men to determine if these genetic changes prevail outside of Sweden. And they caution that the panel of markers cannot tell how aggressive a potential cancer may be.

“This information is not yet available as a genetic test for risk of prostate cancer, but efforts are under way to rapidly develop one,” says William B. Isaacs, Ph.D., of the Johns Hopkins Brady Urological Institute, who participated in the study.

“While these findings need to be validated and refined, it’s a step in the right direction to revealing the genetic-based reasons for this cancer that we have been looking for over the past 15 years,” he added.

In the study, the scientists drew blood from 2,893 prostate cancer patients and 1,781 men without the disease. White blood cells are a good source of DNA that an individual is born with as opposed to DNA in cancer cells that gets altered by the environment or other means, according to the scientists.

Using DNA from blood cells, they sifted through variations in chemicals called nucleotides that pair up to form the rungs of a DNA ladder which carries genetic instructions. These so-called “single nucleotide polymorphisms” or SNPs, occur when one chemical base pair is swapped for another, altering the information in the DNA alphabet or sequence.

Investigators found 16 SNPs in five different regions of human chromosomes 8 and 17 that were more common to men with prostate cancer than those without the disease. The individual changes were ones previously linked to prostate cancer and other diseases, a good indication, the scientists say, that they were on the right track.

To create their panel, the scientists chose the best SNPs from each of the five regions and tested their cumulative effect on prostate cancer risk. As the number of associated SNPs increased, so did risk. Men with four or more of these SNPs were nearly 4.5 times more likely to have prostate cancer.

“This work strongly suggests that because of the combination of polymorphisms we inherit, one man may be more on the path to developing prostate cancer than another,” says Isaacs, who is the William Thomas Gerrard, Mario Anthony Duhon and Jennifer and John Chalsty Professor of Urology at the Brady Urological Institute and professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Add to that a family history of prostate cancer and the risk doubles. Men with all five SNPs plus a family history of prostate cancer were nearly 9.5 times more likely to have the disease. Further analysis revealed that 46 percent of prostate cancer cases in this population were due to these risk factors. But the scientists estimate that almost 90 percent of the Swedish population carries one or more of the five SNPs, elevating their risk for prostate cancer relative to men who carry none of these factors.

Swedish populations are relatively homogenous, tending to marry other Swedes and well suited for such genetic studies because genetic variation is somewhat more limited than in larger, heterogeneous groups. Socialized medicine in Sweden also enables access to robust registries of patient data.

In addition, Swedes suffer from higher-grade prostate and other cancers, and deaths among their Caucasian populations are 10 to 20 percent higher than among American Caucasians, according to Henrik Gronberg, M.D., Ph.D., professor of epidemiology at the Karolinska Institute and a co-investigator on the study.

Isaacs and his team note that the SNPs may not in themselves lead to increased cancer risk, but could be markers linked to other changes that do so.

Wake Forest and Johns Hopkins’ Schools of Medicine have filed patent applications for the technology and results described in this study.

Source: Johns Hopkins Medical Institutions

Scientists find second site for prostate cancer gene
Scientists at Wake Forest University School of Medicine and colleagues who are studying a prostate cancer gene called HNF1B have found a second independent site within the HNF1B gene on chromosome 17 (17q12) – increasing the number of genetic variants that may contribute to risk of developing the disease.
Scientists associate 6 new genetic variants with heart disease risk factor
Using new techniques for rapidly scanning the human genome, researchers have associated levels of cholesterol and triglycerides, two fats in the blood, to 18 genetic variants, six of which represent new DNA regions never before associated with the traits. The findings, appearing in the January 13 advance online issue of Nature Genetics, help explain some of the variability in cholesterol and triglyceride levels that arises from genes.
Study finds gene linked to aggressive prostate cancer
Results from two genome-wide association studies have identified a genetic variant of the DAB2IP gene that is associated with the risk of aggressive prostate cancer. Research teams from the Translational Genomics Research Institute (TGen), Wake Forest University School of Medicine, the Karolinska Institute in Stockholm, Sweden, and Johns Hopkins Medical Institutions made the discovery jointly.
Consortium publishes Phase II map of human genetic variation
The International HapMap Consortium today published analyses of its second-generation map of human genetic variation, which contains three times more markers than the initial version unveiled in 2005. In two papers in the journal Nature, the consortium describes how the higher resolution map offers greater power to detect genetic variants involved in common diseases, explore the structure of human genetic variation and learn how environmental factors, such as infectious agents, have shaped the human genome.
Genome-wide search unearths surprising clues for diabetes and triglycerides
Scientists from the Broad Institute of Harvard and MIT, Lund University and Novartis today announced the discovery of three unsuspected regions of human DNA that contain clear genetic risk factors for type 2 diabetes, and another that is associated with elevated blood triglycerides.
The findings stem from the work of the Diabetes Genetics Initiative (DGI), a public-private partnership established in 2004 between Novartis, the Broad Institute of Harvard and MIT, and Lund University, and also reflect a close partnership with two other diabetes research groups. The three groups’ studies, appearing together in the April 26 advance online edition of Science, are among the first to apply a suite of genomic resources to clinical research, including the Human Genome Project, the SNP and HapMap Projects, and genome-scale laboratory and analytical tools.
Which genome variants matter?
Findings published today in Science will accelerate the search for genes involved in human disease. The report provides a first genome-wide view of how the unique composition of genetic variation within each of us leads to unique patterns of gene activity.
Too much calcium in blood may increase risk of fatal prostate cancer
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.
New discovery about growth factor can be breakthrough for cancer research
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells. This discovery, published in today’s issue of Nature Cell Biology, opens up an entirely new landscape for research on breast and prostate cancer, among other types.

Gene markers located for hereditary prostate cancer

Related stories:

News discussion: